Payment overview · 2025
General Payments
$193.58
9 reported records · 5 companies
Healthcare provider profile · identity verified
Scott D Groesch, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1538107404
Verified facts
What the public records show
CMS Open Payments records show Scott D Groesch, MD received $193.58 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 59.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $114.61 | 59.2% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.58 | 12.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.79 | 11.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.20 | 8.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.40 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $193.58 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $114.61 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $98.31 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
204 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 693 | 191 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 689 | 198 |
| Amlodipine Besylate | Amlodipine Besylate | 682 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 104 |
| Losartan Potassium | Losartan Potassium | 386 | 108 |
| Hydrochlorothiazide | Hydrochlorothiazide | 374 | 99 |
| Omeprazole | Omeprazole | 272 | 76 |
| Gabapentin | Gabapentin | 248 | 60 |
| Lisinopril | Lisinopril | 247 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 223 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 61 |
| Metformin Hcl | Metformin Hcl | 206 | 58 |
| Eliquis | Apixaban | 204 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 196 | 36 |
| Alprazolam | Alprazolam | 190 | 56 |
| Tramadol Hcl | Tramadol Hcl | 179 | 47 |
| Trazodone Hcl | Trazodone Hcl | 169 | 48 |
| Ozempic | Semaglutide | 168 | 32 |
| Simvastatin | Simvastatin | 166 | 49 |
| Sertraline Hcl | Sertraline Hcl | 165 | 45 |
| Allopurinol | Allopurinol | 160 | 46 |
| Metformin Hcl Er | Metformin Hcl | 160 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 45 |
| Famotidine | Famotidine | 132 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 29 |
| Meloxicam | Meloxicam | 124 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 119 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 42 |
| Clonazepam | Clonazepam | 112 | 15 |
| Jardiance | Empagliflozin | 110 | 29 |
| Finasteride | Finasteride | 107 | 29 |
| Furosemide | Furosemide | 105 | 30 |
| Potassium Chloride | Potassium Chloride | 105 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 104 | 20 |
| Bupropion Xl | Bupropion Hcl | 99 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 34 |
| Montelukast Sodium | Montelukast Sodium | 87 | 21 |
| Atenolol | Atenolol | 84 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 65 | 16 |
| Synthroid | Levothyroxine Sodium | 65 | 18 |
| Azithromycin | Azithromycin | 63 | 51 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 18 |
| Mirtazapine | Mirtazapine | 60 | 12 |
| Xarelto | Rivaroxaban | 58 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 17 |
| Propranolol Hcl | Propranolol Hcl | 57 | 18 |
| Donepezil Hcl | Donepezil Hcl | 55 | 11 |
| Lorazepam | Lorazepam | 55 | 13 |
| Prednisone | Prednisone | 55 | 22 |
| Diazepam | Diazepam | 54 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 50 | 50 |
| Valacyclovir | Valacyclovir Hcl | 48 | 23 |
| Buspirone Hcl | Buspirone Hcl | 47 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | 11 |
| Celecoxib | Celecoxib | 44 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 13 |
| Ramipril | Ramipril | 40 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | 12 |
| Valsartan | Valsartan | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 34 | 12 |
| Testosterone | Testosterone | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 11 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 28 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 16 |
| Estradiol | Estradiol | 27 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Nystatin | Nystatin | 27 | 11 |
| Risedronate Sodium | Risedronate Sodium | 27 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $193.58 · 9 records | ABBVIE INC. | MOUNJARO, NURTEC ODT, QULIPTA, UBRELVY, VOQUEZNA, XYOSTED, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error